MLTX — MoonLake Immunotherapeutics
NASDAQ · Healthcare · Biotechnology
$14.88
-$0.25 (-1.65%)
MoonLake Immunotherapeutics (MLTX) is a biotechnology company listed on NASDAQ. It is led by Jorge Santos da Silva Ph.D., based in Dorfstrasse 29, Zug, Switzerland, 6300, with about 130 employees. MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Net income was -$70.7M. MLTX currently screens at market cap $1.41B.
Use this MLTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the MLTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the MLTX SEC filings page. Lician reads the product cache first so this HTML stays unique to MoonLake Immunotherapeutics even when a live quote feed is slow.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Key Statistics
Market Cap
$1.41B
Volume
389,402
Previous Close
$15.62
Day Range
$15.47 – $15.78
EPS
-$1.89
Revenue
$0.00
Net Income
-$121.24M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
130
MLTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$121.24M | -$44.08M | -$64.51M | -$53.64M |
| EPS (Diluted) | -$1.89 | -$0.73 | -$1.70 | -$6.84 |
Total Assets
$477.93M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$180.43M
Operating Cash Flow
-$116.59M
Free Cash Flow
$0.00
MoonLake Immunotherapeutics Company Information
- Co-Founder, Interim Chair of the Board & CEO
- Jorge Santos da Silva Ph.D.
- Headquarters
- Dorfstrasse 29, Zug, Switzerland, 6300
- Website
- www.moonlaketx.com
- Phone
- 41 415108022
- IPO / Founded
- 2020-10-20
- Sector
- Healthcare
- Industry
- Biotechnology